Tyrosine kinase inhibitor‐induced IL‐6/STAT3 activation decreases sensitivity of EGFR‐mutant non‐small cell lung cancer to icotinib

Jinyao Wang(First Hospital of China Medical University), Xiaofang Che(First Hospital of China Medical University), Tieqiong Zhang(First Hospital of China Medical University), Xuejun Hu(Zoucheng People's Hospital), Jian Kang(First Hospital of China Medical University), Yizhe Wang(First Hospital of China Medical University), Kezuo Hou(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Chunlei Zheng(First Hospital of China Medical University)
Cell Biology International
June 9, 2018
10.1002/cbin.11000
Cited by 21

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417